News

Achaogen Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of up to 5,000,000 shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

2017-08-07T14:58:13+00:00